Intrathecal administration of AS1928370, a transient receptor potential vanilloid 1 antagonist, attenuates mechanical allodynia in a mouse model of neuropathic pain

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 7, 2011, Pages 1105-1108

  Watabiki, Tomonari ^a   Kiso, Tetsuo ^a   Tsukamoto, Mina ^a   Aoki, Toshiaki ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Capsaicin; Intrathecal; Neuropathic pain; Transient receptor potential vanilloid 1

Indexed keywords

ASI 928370; N (1 METHYL 2 OXO 1,2,3,4 TETRAHYDRO 7 QUINOLYL) 2 [(2 METHYLPYRROLIDIN 1 YL)METHYL]BIPHENYL 4 CARBOXAMIDE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; HOT PLATE TEST; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; RECEPTOR BLOCKING;

ANIMALS; BENZAMIDES; CAPSAICIN; DISEASE MODELS, ANIMAL; HYPERALGESIA; INJECTIONS, SPINAL; MICE; NEURALGIA; QUINOLONES; TISSUE DISTRIBUTION; TRPV CATION CHANNELS;

EID: 79960306015     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.1105     Document Type: Article

References (20)

1. Caterina M. J., Schumacher M. A., Tominaga M., Rosen T. A., Levine J. D., Julius D., Nature (London), 389, 816-824 (1997).
2. Sasamura T., Kuraishi Y., Jpn. J. Pharmacol., 80, 275-280 (1999).
3. Tominaga M., Caterina M. J., Malmberg A. B., Rosen T. A., Gilbert H., Skinner K., Raumann B. E., Basbaum A. I., Julius D., Neuron, 21, 531-543 (1998).
4. Huang S. M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T. J., Krey J. F., Chu C. J., Miller J. D., Davies S. N., Geppetti P., Walker J. M., Di Marzo V., Proc. Natl. Acad. Sci. U.S.A., 99, 8400-8405 (2002).
5. Wong G. Y., Gavva N. R., Brain Res. Rev., 60, 267-277 (2009).
6. Garami A., Shimansky Y. P., Pakai E., Oliveira D. L., Gavva N. R., Romanovsky A. A., J. Neurosci., 30, 1435-1440 (2010).
7. Watabiki T., Kiso T., Kuramochi T., Yonezawa K., Tsuji N., Kohara A., Kakimoto S., Aoki T., Matsuoka N., J. Pharmacol. Exp. Ther., 336, 743-750 (2011).
8. Kiso T., Watabiki T., Tsukamoto M., Okabe M., Kagami M., Nishimura K., Aoki T., Matsuoka N., Neuroscience, 153, 492-500 (2008).
9. Hylden J. L., Wilcox G. L., Eur. J. Pharmacol., 67, 313-316 (1980).
10. Sakurada T., Katsumata K., Tan-No K., Sakurada S., Kisara K., Neuropharmacology, 31, 1279-1285 (1992).
11. Chaplan S. R., Bach F. W., Pogrel J. W., Chung J. M., Yaksh T. L., J. Neurosci. Methods, 53, 55-63 (1994).
12. Palazzo E., Rossi F., Maione S., Mol. Cell. Endocrinol., 286, S79-S83 (2008).
13. Davis J. B., Gray J., Gunthorpe M. J., Hatcher J. P., Davey P. T., Overend P., Harries M. H., Latcham J., Clapham C., Atkinson K., Hughes S. A., Rance K., Grau E., Harper A. J., Pugh P. L., Rogers D. C., Bingham S., Randall A., Sheardown S. A., Nature (London), 405, 183-187 (2000).
14. Pomonis J. D., Harrison J. E., Mark L., Bristol D. R., Valenzano K. J., Walker K., J. Pharmacol. Exp. Ther., 306, 387-393 (2003).
15. Honore P., Wismer C. T., Mikusa J., Zhu C. Z., Zhong C., Gauvin D. M., Gomtsyan A., El Kouhen R., Lee C. H., Marsh K., Sullivan J. P., Faltynek C. R., Jarvis M. F., J. Pharmacol. Exp. Ther., 314, 410-421 (2005).
16. Hudson L. J., Bevan S., Wotherspoon G., Gentry C., Fox A., Winter J., Eur. J. Neurosci., 13, 2105-2114 (2001).
17. Rashid M. H., Inoue M., Bakoshi S., Ueda H., J. Pharmacol. Exp. Ther., 306, 709-717 (2003).
18. Kelly S., Chapman V., Brain Res., 935, 103-108 (2002).
19. Kanai Y., Nakazato E., Fujiuchi A., Hara T., Imai A., Neuropharmacology, 49, 977-984 (2005).
20. Kanai Y., Hara T., Imai A., Sakakibara A., J. Pharmacol. Exp. Ther., 59, 733-738 (2007).